Decision on the Adoption of a Sale Plan for Pixium Vision Postponed

Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.

Pixium draws investors’ attention to the fact that, given the price offered by the prospective buyer and the company’s level of indebtedness, the sale proceeds received in the event of a favorable decision by the Commercial Court will not allow a total or partial reimbursement of shareholders.

Pixium Vision is the developer of bionic vision systems designed to enable those who have lost thier sight to regain visual perception and greater autonomy. The Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (AMD).